Your browser doesn't support javascript.
loading
Paraneoplastic pemphigus and Castleman's disease: a case report and a revision of the literature.
Irrera, Mariangela; Bozzola, Elena; Cardoni, Antonello; DeVito, Rita; Diociaiuti, Andrea; El Hachem, Maya; Girardi, Katia; Marchesi, Alessandra; Villani, Alberto.
Afiliação
  • Irrera M; Pediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Bozzola E; Pediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. elena.bozzola@opbg.net.
  • Cardoni A; Unity of Pathology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • DeVito R; Unity of Pathology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Diociaiuti A; Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • El Hachem M; Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Girardi K; Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Marchesi A; Pediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Villani A; Pediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Ital J Pediatr ; 49(1): 33, 2023 Mar 20.
Article em En | MEDLINE | ID: mdl-36941723
ABSTRACT

BACKGROUND:

In literature, a few reports described an association between paraneoplastic pemphigus (PNP) and Castelman's disease (CD), but no consensus have been proposed for the diagnostic-therapeutical approach. Aim of this study is to present a case report and explore the relationship between PNP and CD in pediatric patients, focusing on clinical manifestations, histopathological findings, treatment and outcome to find elements for an early diagnosis. CASE PRESENTATION We present the clinical case of a 13 years old girl with a challenging diagnosis of PNP and CD who underwent therapy at first with Rituximab and then with Siltuximab, for the control of symptoms.

CONCLUSIONS:

Reviewing literature, 20 clinical cases have been described in the pediatric age. Diagnosis may be challenging, requiring an average of 3 months (range from 3 weeks to 2 years). In all cases, the initial manifestations were mucocutaneous lesions, especially oral lesions with poor response to conventional treatment. Systemic symptoms may be present as well. Therapeutical approach is still discussed with no consensus. Almost all patients received corticosteroids with poor response. Other drugs including azathioprine, methotrexate, cyclosporine and monoclonal antibodies have been evaluated for the control of the disease. Further studies and experimental trials urge to define the diagnostic criteria and therapy protocol.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hiperplasia do Linfonodo Gigante / Pênfigo Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Screening_studies Limite: Adolescent / Child / Female / Humans Idioma: En Revista: Ital J Pediatr Assunto da revista: PEDIATRIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hiperplasia do Linfonodo Gigante / Pênfigo Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Screening_studies Limite: Adolescent / Child / Female / Humans Idioma: En Revista: Ital J Pediatr Assunto da revista: PEDIATRIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália